GI Medical Calculator 对比 Hypercholesterolemia 的使用情况和统计数据

GI Medical Calculator App is an application that conducts accessible and instant calculations of various laboratory results. This medical calculator is an innovative tool to help doctors deliver automated computations of the patients’ laboratory results.
  • Apple 应用商店
  • 免费
  • 医疗

商店排名

- -

@Point of Care™ with Cognitive AI is a clinical decision-making mobile platform. Hypercholesterolemia @Point of Care™ provides a streamlined clinical decision support tool for clinicians to obtain content when it is needed—enabling better decisions, better outcomes, and better care. With Cognitive AI, clinicians use @Point of Care™ to easily access curated, evidence-based, and disease-specific medical content. Clinicians navigate content by asking voice-enabled natural language questions. With Cognitive AI, confidence-rated answers to efficiently incorporate best treatment options happen more quickly and decisions are made faster to improve patient outcomes at the point of care. Hypercholesterolemia @Point of Care™ is designed to: • Support discovery and practice change • Provide relevant, evidence-based disease-specific medical content • Improve patient outcomes at the point of care Features: • Continually updated Hypercholesterolemia content • Topics in diagnosis, treatment, and care management developed with expert physician authors • Case studies, videos, and interviews • Access to actionable patient-recorded data • Detailed reference list with access to original sources • Continuing medical education credit (CME/CE) • Surveys and peer polling • Patient education resources to share with patients
  • Apple 应用商店
  • 免费
  • 医疗

商店排名

- -

GI Medical Calculator与Hypercholesterolemia排名比较

对比 GI Medical Calculator 与 Hypercholesterolemia 在过去 28 天内的排名趋势

排名

没有可用的数据

GI Medical Calculator 对比 Hypercholesterolemia 的排名,按国家/地区比较

对比 GI Medical Calculator 与 Hypercholesterolemia 在过去 28 天内的排名趋势

无数据可显示

通过免费试用版比较任何网站

开始使用
GI Medical Calculator VS.
Hypercholesterolemia

十二月 19, 2024